Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Hold" by Brokerages
Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) has earned an average recommendation of "Hold" from the five research firms that are presently covering the firm, Marketbeat reports. One...